NGM Biopharmaceuticals (NYSE:NGM) Shares Up 9.3%

Share on StockTwits

NGM Biopharmaceuticals (NYSE:NGM) shares shot up 9.3% during trading on Thursday . The company traded as high as $14.40 and last traded at $14.15, 230,453 shares were traded during trading. An increase of 99% from the average session volume of 115,813 shares. The stock had previously closed at $12.95.

A number of brokerages recently commented on NGM. Stifel Nicolaus reaffirmed a “buy” rating and set a $26.00 price objective on shares of NGM Biopharmaceuticals in a research report on Wednesday, August 14th. B. Riley began coverage on shares of NGM Biopharmaceuticals in a research report on Thursday, October 17th. They set a “buy” rating and a $24.00 price objective on the stock. Finally, Zacks Investment Research raised shares of NGM Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research report on Tuesday, August 27th. Six research analysts have rated the stock with a buy rating, NGM Biopharmaceuticals has an average rating of “Buy” and an average price target of $24.17.

The stock’s 50-day moving average is $12.52 and its 200 day moving average is $14.19.

NGM Biopharmaceuticals (NYSE:NGM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.11. The company had revenue of $21.57 million for the quarter, compared to analysts’ expectations of $17.50 million.

In related news, major shareholder Group L. P. Column sold 30,926 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $77.72, for a total transaction of $2,403,568.72. Also, Director Peter Svennilson bought 84,939 shares of NGM Biopharmaceuticals stock in a transaction on Monday, October 21st. The stock was acquired at an average price of $11.75 per share, with a total value of $998,033.25. Over the last ninety days, insiders have purchased 264,922 shares of company stock worth $2,872,650 and have sold 101,691 shares worth $3,074,961.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Essex Investment Management Co. LLC acquired a new stake in NGM Biopharmaceuticals in the third quarter valued at approximately $621,000. Nisa Investment Advisors LLC acquired a new stake in NGM Biopharmaceuticals in the third quarter valued at approximately $81,000. Royal Bank of Canada acquired a new stake in NGM Biopharmaceuticals in the second quarter valued at approximately $17,691,000. Svennilson Peter acquired a new stake in shares of NGM Biopharmaceuticals in the second quarter worth $229,762,000. Finally, Victory Capital Management Inc. acquired a new stake in shares of NGM Biopharmaceuticals in the second quarter worth $1,870,000.

About NGM Biopharmaceuticals (NYSE:NGM)

NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity.

Featured Story: What is diluted earnings per share (Diluted EPS)?

Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.